Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Vitekta

(Elvitegravir)

Small molecule

0

Indications

1

Total Trials

0

Active Trials

0

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

5

Patents

Clinical

Trials by Indication[1]

Safety and Efficacy1 trial

Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir

Completed· Gilead logo

Gilead·Phase 3·NCT00708162·724 enrolled

Regulatory

FDA Approval Timeline[3]

Sep 24, 2014

VITEKTA

NDA NDA203093

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Elvitegravir. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Elvitegravir compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
OpenFDA — FDA approval records (NDA NDA203093). U.S. Food & Drug Administration.
[4]
FDA Orange Book — Patent and exclusivity data for Vitekta. U.S. Food & Drug Administration.
[5]
SEC EDGAR — Gilead company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: Gilead

Patent Landscape[4]

Patent Cliff

Feb 27, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

7635704Oct 26, 2026

8981103Oct 26, 2026

7176220*PEDFeb 27, 2027

7635704*PEDApr 26, 2027

8981103*PEDApr 26, 2027

Related News